Dr. Bergsagel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13400 E Shea Blvd
Scottsdale, AZ 85259Phone+1 480-301-8000
Summary
- Dr. Peter Bergsagel is an oncologist in Scottsdale, AZ and is affiliated with Mayo Clinic Hospital. He received his medical degree from University of Toronto Faculty of Medicine and has been in practice 33 years. He is experienced in multiple myeloma.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
- Stanford Health Care-Sponsored Stanford UniversityInternship, Internal Medicine, 1985 - 1986
- University of Toronto Faculty of MedicineClass of 1984
- Trinity College, University of TorontoB.S., 1977 - 1980
Certifications & Licensure
- AZ State Medical License 2004 - 2026
- CA State Medical License 2024 - 2026
- NY State Medical License 1995 - 2006
- WV State Medical License 1990 - 1996
- MD State Medical License 1988 - 1990
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- Top Doctors:Arizona State Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
- Join now to see all
Clinical Trials
- Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis Start of enrollment: 2013 Aug 20
- A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2017 Dec 15
- A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Roles: Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 61 citationsCarfilzomib and the cardiorenal system in myeloma: an endothelial effect?Allison C. Rosenthal, J Luthi, Marek Belohlavek, Klaus Martin Kortüm, Farouk Mookadam
Blood Cancer Journal. 2016-01-15 - 492 citationsNonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signalingSivakumar Vallabhapurapu, Atsushi Matsuzawa, Weizhou Zhang, Ping Hui Tseng, Jonathan J Keats
Nature Immunology. 2008-11-09 - 106 citationsCompromised stem cell mobilization following induction therapy with lenalidomide in myelomaH. Paripati, Alexander Keith Stewart, S Cabou, Amylou C. Dueck, Victor J Jimenez Zepeda
Leukemia. 2008-01-24
Journal Articles
- Inhibitors of the Protein Disulfide Isomerase Family for the Treatment of Multiple MyelomaPeter Bergsagel, MD, Nature
- Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
- Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growthVallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas DR, Orlowski RZ, Chesi M, Kuehl WM, Bergsagel PL, Karin M, Vallabha..., Nature Communications, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Interim analysis of a phase ii trial of nab-paclitaxel in patients with very advanced relapsed/refractory multiple myeloma (rr-mm)Rosenthal AC, Fonseca R, Mikhael J, Stewart AK, Mayo A, Chesi M, Kosiorek H, Bergsagel PL, J Clin Oncol, 1/20/2015
- Uch-l1 synergizes with bcl6 and predicts a poor outcome in diffuse large b-cell lymphomaBedekovics T, Hussain S, Feldman AL, Chesi M, Bergsagel PL, Galardy PJ, Br J Haematol, 1/1/2015
- Targeting genetic heterogeneity in multiple myeloma through immune activationChesi M, Bergsagel PL, Clin Cancer Res, 1/1/2015
- Join now to see all
Grant Support
- Mouse Model Of Age-Associated Monoclonal GammopathyNational Institute On Aging2010–2012
- Molecular Pathogenesis Of Multiple MyelomaNational Cancer Institute2009–2012
- Comparative Pharmaco-Oncogenomics Of Myeloma Drug ResistanceNational Cancer Institute2009–2012
- P-4: Targeting Activation Of NFKB Pathways In MMNational Cancer Institute2008–2011
- Mouse Models Of Age-Associated Monoclonal GammopathyNational Institute On Aging2009
- Mouse Models Of Age-Associated Monoclonal GammopathyNational Institute On Aging2005–2007
- Mouse Models Of Age-Associated Monoclonal GammopathyNational Institute On Aging2003–2004
- Molecular Pathogenesis Of Plasma Cell NeoplasmsNational Cancer Institute1997–2001
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: